Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | COO and CFO | October 19, 2017 | October 23, 2017 |
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director · Chief Executive Officer | September 16, 2026 | September 18, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director · CEO & President | March 08, 2024 | March 13, 2024 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | See Remarks | March 04, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date October 19, 2017 · Filed October 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,269 |
Reported balance
After 2017-10-19 transaction · row 1
1 source rowRow 1 · 2017-10-19 · Sale · Disposed 1,326 · Balance 201,269 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 271,765 |
Ending reported balance
After 2026-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,610 · Balance 279,602 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-09-18 · Sale · Disposed 7,837 · Balance 271,765 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Dyne Therapeutics, Inc.
Report date March 08, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 708,316 |
Reported balance
After 2024-03-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-08 · Exercise / conversion · Acquired 153,931 · Balance 708,316 |
| Common StockSEC Table I · non-derivative | Direct | 917,728 |
Reported balance
After 2024-03-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-03-08 · Exercise / conversion · Acquired 209,412 · Balance 917,728 |
| Common StockSEC Table I · non-derivative | Direct | 715,490 |
Reported balance
After 2024-03-08 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-03-08 · Sale · Disposed 202,238 · Balance 715,490 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 554,820 |
Reported balance
After 2024-03-08 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2024-03-08 · Sale · Disposed 160,670 · Balance 554,820 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 554,385 |
Reported balance
After 2024-03-08 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2024-03-08 · Sale · Disposed 435 · Balance 554,385 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 604,385 |
Reported balance
After 2024-03-11 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2024-03-11 · Exercise / conversion · Acquired 50,000 · Balance 604,385 |
| Common StockSEC Table I · non-derivative | Direct | 564,313 |
Reported balance
After 2024-03-11 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2024-03-11 · Sale · Disposed 40,072 · Balance 564,313 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 554,385 |
Reported balance
After 2024-03-11 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2024-03-11 · Sale · Disposed 9,928 · Balance 554,385 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 546,616 |
Reported balance
After 2024-03-11 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2024-03-11 · Sale · Disposed 7,769 · Balance 546,616 F6: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 537,998 |
Reported balance
After 2024-03-11 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2024-03-11 · Sale · Disposed 8,618 · Balance 537,998 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive. F9: Includes 513,913 unvested RSUs. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 0 |
Reported balance
After 2024-03-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-08 · Exercise / conversion · Disposed 153,931 · Balance 0 F10: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 133,269 |
Reported balance
After 2024-03-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-08 · Exercise / conversion · Disposed 209,412 · Balance 133,269 F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 83,269 |
Reported balance
After 2024-03-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-11 · Exercise / conversion · Disposed 50,000 · Balance 83,269 F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive.
F6: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive.
F9: Includes 513,913 unvested RSUs.
F10: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020.
Kaleido Biosciences, Inc.
Report date March 04, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-03-04 | Direct | 80,000 |
Reported balance
After 2019-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 80,000 · Balance 80,000 F1: 25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2016 Filed Dec 29, 2016 18:15 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 990 | $15.85 | $15,691.50 |
DisclosureSEC source: 0001209191-16-157040 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,824 F1 · kind: Sale to cover taxes associated with RSU vesting. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 17:18 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 3,021 | $13.25 | $40,028.25 |
DisclosureSEC source: 0001209191-16-154219 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,814 Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 17:59 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-145833 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,835 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 33.33%, 33.33% and 33.34% of the shares subject to the award vest on each of the first, second and third anniversaries of the vesting commencement date, respectively, subject to the officer's continuous service on each applicable vesting date. The vesting commencement date for the awards is the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.